Tirzepatide vs Semaglutide.
Tirzepatide (Zepbound/Mounjaro) vs Wegovy (Semaglutide): comparing the FDA-approved branded drugs for weight loss — mechanisms, efficacy, cost, and availability.
Quick Verdict
Zepbound (Tirzepatide) outperforms Wegovy (Semaglutide) on weight loss (~20% vs ~15% body weight) due to dual GLP-1/GIP mechanism. Both are FDA-approved. Tirzepatide is often better tolerated. Choose Wegovy first for established safety profile; upgrade to Zepbound for maximum efficacy.
Side-by-Side Analysis
| Dimension | Tirzepatide | Semaglutide |
|---|---|---|
| Mechanism | Dual receptor agonism at GLP-1 and GIP receptors for synergistic appetite suppression, improved insulin sensitivity, and enhanced metabolic function. | GLP-1 receptor agonism mimics the incretin hormone to reduce appetite, slow gastric emptying, improve insulin sensitivity, and provide cardiovascular protection. |
| Primary Benefits | Weight loss, body recomposition, glycemic control | Fat loss, appetite control, cardiovascular benefits |
| Typical Dose | 2500–2500mcg | 250–250mcg |
| Route | SubQ | SubQ |
| Frequency | 1x/wk | 1x/wk |
| Half-Life | 120 hours | 168 hours |
| FDA Status | Approved | Approved |
| Evidence Grade | very-strong | very-strong |
| Key Studies | 20+ indexed | 20+ indexed |
| Lowest Price | $69.99 / 5mg via Amino Club | $47.99 / 5mg via Amino Club |
Which one should you choose?
Who Should Choose Tirzepatide?
Choose Tirzepatide (Zepbound/Mounjaro) if:
- Maximum weight loss efficacy is the priority
- You've plateaued on semaglutide
- GI side effects of Wegovy have been intolerable (Tirzepatide often gentler)
- You have comorbid T2DM (Mounjaro is approved for glycemic control)
Who Should Choose Semaglutide?
Choose Semaglutide (Wegovy/Ozempic) if:
- You want the most established long-term safety data (SUSTAIN, STEP trials)
- Cost is a major consideration (Wegovy may have more insurance coverage)
- You are starting a GLP-1 protocol for the first time
- Once-weekly injection is the primary convenience driver
Can you stack Tirzepatide + Semaglutide?
Never stack Tirzepatide and Semaglutide — they share the GLP-1 receptor. Stacking creates dangerous additive GLP-1 stimulation risk: severe nausea, hypoglycemia, and cardiovascular complications. They are mechanistic competitors, not complements.
Vendor Pricing
· Affiliate links · Prices verified 2026Tirzepatide
2 vendorsSemaglutide
2 vendorsAffiliate disclosure: PeptiDex may earn a commission from purchases via vendor links at no extra cost to you. See our methodology.
Frequently Asked Questions
The SURMOUNT-1 trial showed Tirzepatide (Zepbound) achieved ~20% body weight loss vs Wegovy's ~15% in the STEP 1 trial. Head-to-head trials (SURPASS-CVOT) confirm Tirzepatide's superior efficacy.